logo-loader

Advanced Oncotherapy hires director with 35-year track record of “commercialising disruptive med-tech”

Published: 02:55 29 Sep 2020 EDT

Advanced Oncotherapy PLC -

Advanced Oncotherapy PLC (LON:AVO) is appointing a new independent director with a 35-year track record of “commercialising disruptive med-tech”.

As the founder of MindSpan Consulting, Lori Cross’ client base includes Thermo Fisher Scientific, Medtronic, Nestle Healthcare, Danaher Beckman, GE Healthcare, and Novartis.

Meanwhile, her experience working at companies such as VIASYS Healthcare, Smith & Nephew, and Baxter Edwards Laboratories will be invaluable in her new role helping guide a team rolling out the next-generation proton therapy systems for cancer treatment.

“Lori brings over 35 years of experience in commercialising disruptive MedTech innovations and her expertise will be invaluable to our business as we continue to progress the LIGHT system and develop commercial partnerships,” said Advanced Oncotherapy chairman, Dr Mike Sinclair.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 14 minutes ago